Welcome to our dedicated page for Well Health Tech news (Ticker: WHTCF), a resource for investors and traders seeking the latest updates and insights on Well Health Tech stock.
WELL Health Technologies Corp. (WHTCF) is a digital healthcare company that frequently issues detailed updates on its clinic operations, technology platform, and financial performance. News about WELL often highlights developments across its Canadian Patient Services segment, its U.S. specialty markets, and its majority‑owned SaaS subsidiary, WELLSTAR Technologies Corp.
Investors following WHTCF news can expect regular coverage of quarterly results, including trends in revenue, adjusted EBITDA, and patient visits across the company’s clinic network. WELL also reports on clinic acquisitions, expansion of its Canadian clinics platform, and changes to its senior secured credit facility that support its acquisition pipeline and growth plans.
Another major theme in WELL’s news flow is clinic digitization and AI‑enabled tools. The company provides updates on the progress of digital transformation in its primary care clinics, including adoption of online booking, self‑check‑in, digital reminders, and digital consents. It also announces new AI‑powered products and deployments across its network, such as AI ambient scribe solutions and decision support tools.
WELLSTAR‑related announcements are an important component of WELL’s news. These items cover WELLSTAR’s recurring revenue growth, new contracts for digital health platforms, acquisitions of SaaS and billing assets, and equity financings intended to fund future growth and potential spin‑out plans. Together, these updates offer insight into WELL’s combined strategy of operating a large outpatient clinic network while scaling a healthcare technology platform.
For readers tracking WHTCF, this news page aggregates company press releases and market‑moving updates in one place, making it easier to review WELL’s operational milestones, technology initiatives, and capital markets activity over time.
Medtech capital is shifting toward validated, deployable platforms as regulators emphasize real-world evidence. Venture investment reached roughly $10.4 billion in 2025, and the FDA advanced its real-world evidence framework for devices. Key developments include VentriPoint's Edison Gold for its VMS+™ 4.0 cardiac imaging platform and 10x Genomics' STELA spatial-biobank initiative.
Other notable items: Senseonics reported multi‑sensor real‑world CGM adherence data, TransMedics launched a controlled hypothermic organ-preservation device, and WELL Health posted record Canadian visits and margin expansion.
WELL Health Technologies (TSX: WELL / OTCQX: WHTCF) will release Fiscal Q1 2026 results for the period ended March 31, 2026, after market close on Thursday, May 7, 2026. A conference call and simultaneous webcast are scheduled the same day at 5:00 PM ET / 2:00 PM PT.
Management participants include Hamed Shahbazi, Chairman and CEO, and Eva Fong, CFO. Dial-in details and webcast registration are provided for investors and analysts.
WELL Health (OTCQX: WHTCF) reported record Canadian performance in Q1-2026: ~1.27 million patient visits (33% YoY, 13% organic) and Primary Care Adjusted EBITDA margins of ~8%, up ~200 basis points year-over-year. Affiliate clinics expanded to 74 locations and the provider base reached 3,158.
CardiologyNow virtual consultations grew 65% YTD; results are preliminary and subject to final reporting and adjustment.
WELL (OTCQX: WHTCF) subsidiary CYBERWELL launched its CYDEcore™ Fusion platform and announced a unified operating model consolidating Cycura, Seekintoo, and Proack into one cybersecurity business.
Key milestones include SOC2 Type I certification, Microsoft Security Solutions Partner designation, and an XSOAR-based managed security platform with multiple enterprise clients live.
WELL Health Technologies (OTCQX: WHTCF) and majority-owned subsidiary WELLSTAR will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026.
WELL presents April 22 at 9:30-10:00 AM ET (Room 104 C/D, presenter Hamed Shahbazi). WELLSTAR presents April 22 at 10:30-11:00 AM ET (Room 104 C/D, presenter Amir Javidan). Both companies will deliver corporate presentations and hold one-on-one investor meetings.
WELL Health (OTCQX: WHTCF) partnered with AliveCor to provide AI-powered Kardia ECG monitoring with cardiologist-reviewed Clinician Reviews for Canadian users starting April 2, 2026.
Canadian-registered cardiologists in WELL’s network review Kardia ECGs within 24 hours, supplementing AI results (Kardia: >350 million ECGs recorded; AI detects three common arrhythmias) and generating clinical services revenue per review.
WELL Health (TSX: WHTCF) supports Ontario’s plan for a provincewide Primary Care Medical Record system backed by $3.4 billion in primary care funding to connect about 2 million more residents by 2029. WELL says its majority-owned WELLSTAR already supports ~8,165 physicians and 1,669 clinics in Ontario via provincially certified EMRs.
WELL intends to participate in the Province’s open, multi-vendor procurement led by Supply Ontario, citing its OSCAR Pro, Nexus AI™, OceanMD and broader WELL ecosystem as fit-for-purpose for interoperability, referrals, AI-enabled workflows and cybersecurity.
WELL Health Technologies (OTCQX: WHTCF) reported record FY2025 results with $1.40B revenue (+52% YoY) and $203.7M Adjusted EBITDA (+336% YoY; 14.5% margin). Canadian Patient Services revenue rose to $444.3M (+39%) with Adjusted EBITDA of $58.1M (+43%). Operating free cash flow to shareholders was $58.2M. Management provided 2026 guidance of $1.55–1.65B revenue and $175–185M Adjusted EBITDA, and completed credit facility expansion to $400M. The company cited acquisitions, organic growth and HEALWELL inclusion as drivers and plans a WELLSTAR spin-out.
WELL Health (OTCQX: WHTCF) said majority-owned WELLSTAR completed two billing acquisitions—PatientSERV (Ontario) and Lambert (Québec)—expanding billing coverage to six provinces. Total consideration was ~$4.8M plus up to $6.3M in contingent payouts. The assets are expected to add ~$5M revenue with EBITDA margins approaching 20%, taking WELLSTAR to an annualized run-rate of ~$84M. WELLSTAR also has a $62M equity financing and reaffirms the planned spin-out and a target $100M revenue run-rate by year-end.
WELL Health (TSX: WELL; OTCQX: WHTCF) will release its Fiscal Fourth Quarter and Year End 2025 results for the period ended December 31, 2025 before market open on Thursday, March 19, 2026. A conference call and webcast to discuss results is scheduled the same day at 1:00 PM ET / 10:00 AM PT, hosted by CEO Hamed Shahbazi and CFO Eva Fong. Investors are asked to dial in 10 minutes early or register to attend the webcast at well.company/events.